• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Transition Therapeutics - Articles and news items

ELND005

Phase 2/3 study of ELND005 did not meet primary efficacy endpoint

Industry news / 24 June 2015 / Victoria White

A Phase 2/3 clinical study of ELND005 in agitation and aggression in patients with Alzheimer’s disease (AD) did not meet its primary efficacy endpoint…

tt701-muscle

Lilly sells muscle strengthening drug TT701 to Transition Therapeutics

Industry news / 11 May 2015 / Victoria White

Transition Therapeutics has exclusively licensed worldwide rights to a novel small molecule drug candidate, TT701, from Eli Lilly and Company…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +